CoChat

A Personalized Preclinical Model to Evaluate the Metastatic Potential of Patient-Derived Colon Cancer Initiating Cells

Puig, Isabel, Chicote, Irene, Tenbaum, Stephan P., Arqués, Oriol, Herance, José Raúl, Gispert, Juan D., Jimenez, José, Landolfi, Stefania, Caci, Karina, Allende, Helena, Mendizabal, Leire, Moreno, Debora, Charco, Ramón, Espín, Eloy, Prat, Aleix, Elez, Maria Elena, Argilés, Guillem, Vivancos, Ana, Tabernero, Josep, Rojas, Santiago, Palmer, Héctor G. · 2013 · Clinical Cancer Research
Cited by 86

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Purpose: Within the aim of advancing precision oncology, we have generated a collection of patient-derived xenografts (PDX) characterized at the molecular level, and a preclinical model of colon cancer metastasis to evaluate drug-response and tumor progression. Experimental Design: We derived cells from 32 primary colorectal carcinomas and eight liver metastases and generated PDX annotated for their clinical data, gene expression, mutational, and histopathological traits. Six models were injected orthotopically into the cecum wall of NOD-SCID mice in order to evaluate metastasis. Three of them were treated with chemotherapy (oxaliplatin) and three with API2 to target AKT activity. Tumor growth and metastasis progression were analyzed by positron emission tomography (PET). Results: Patient-derived cells generated tumor xenografts that recapitulated the same histopathological and genetic features as the original patients' carcinomas. We show an 87.5% tumor take rate that is one of the highest described for implanted cells derived from colorectal cancer patients. Cecal injection generated primary carcinomas and distant metastases. Oxaliplatin treatment prevented metastasis and API2 reduced tumor growth as evaluated by PET. Conclusions: Our improved protocol for cancer cell engraftment has allowed us to build a rapidly expanding collection of colorectal PDX, annotated for their clinical data, gene expression, mutational, and histopathological statuses. We have also established a mouse model for metastatic colon cancer with patient-derived cells in order to monitor tumor growth, metastasis evolution, and response to treatment by PET. Our PDX models could become the best preclinical approach through which to validate new biomarkers or investigate the metastatic potential and drug-response of individual patients. Clin Cancer Res; 19(24); 6787–801. ©2013 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-12-1740

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 86

Metadata

Authors
Puig, I., Chicote, I., Tenbaum, S. P., Arqués, O., Herance, J. R., Gispert, J. D., Jimenez, J., Landolfi, S., Caci, K., Allende, H., Mendizabal, L., Moreno, D., Charco, R., Espín, E., Prat, A., Elez, M. E., Argilés, G., Vivancos, A., Tabernero, J., Rojas, S., & Palmer, H. G.
Venue
Clinical Cancer Research
Published
2013-12-15
Volume
19
Issue
24
Pages
6787-6801
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2156890152
Cited by
86
References
7
FWCI
2.69
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Personalized Preclinical Model to Evaluate the Metastatic Potential of Patient-Derived Colon Cancer Initiating Cells. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-12-1740
The paper
Puig, I., Chicote, I., Tenbaum, S. P., Arqués, O., Herance, J. R., Gispert, J. D., Jimenez, J., Landolfi, S., Caci, K., Allende, H., Mendizabal, L., Moreno, D., Charco, R., Espín, E., Prat, A., Elez, M. E., Argilés, G., Vivancos, A., Tabernero, J., . . . Palmer, H. G. (2013). A Personalized Preclinical Model to Evaluate the Metastatic Potential of Patient-Derived Colon Cancer Initiating Cells. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-12-1740

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.